



Supplementary Table S1. Pharmacotherapy of comorbidities in RPH participants ($n = 29$).


Class of medication	n (%)
Proton pump inhibitors	5 (17)
Antidepressant/antipsychotics	5 (17)
Thyroid substitution (levothyroxine)	4 (13)
Bronchodilator	2 (7)
ACE inhibitor/calcium channel blocker	2 (7%)
Statin	2 (7%)
Beta receptor blocker	1 (3%)
Methotrexate	1 (3%)

LEGEND: ACE, angiotensin-converting enzyme.

Supplementary Table S2. Blood glucose, insulin, and C-peptide concentration during 5-h OGTT in individuals with RPH at baseline and at follow-up.

Time (min)	Glucose (mmol/L)				Insulin (mU/L)				C-peptide (nmol/L)			
	1.	Visit Up	Follow	p -Value	1.	Visit Up	Follow	p -Value	1.	Visit Up	Follow	p -Value
0		4.9 ± 0.5	4.7 ± 0.7	0.121		4.5 ± 3.2	4.4 ± 4.2	0.977		0.5 ± 0.1	0.5 ± 0.2	0.756
30		7.2 ± 1.5	7.1 ± 2.0	0.822		39.7 ± 22.9	43.0 ± 17.6	0.614		2.0 ± 0.7	2.2 ± 0.6	0.262
60		6.7 ± 2.5	6.5 ± 2.5	0.581		64.6 ± 30.5	52.6 ± 18.5	0.149		3.1 ± 0.9	2.9 ± 0.7	0.312
120		5.0 ± 1.6	4.9 ± 1.7	0.847		47.4 ± 49.0	43.7 ± 26.0	0.743		2.6 ± 1.3	2.6 ± 1.0	0.978
180		3.6 ± 1.1	3.3 ± 0.9	0.174		14.8 ± 14.0	13.5 ± 11.2	0.633		1.2 ± 0.8	1.1 ± 0.7	0.364
240		$4.2 \pm 0.5^*$	$3.7 \pm 0.7^*$	0.007*		5.5 ± 5.5	5.8 ± 5.1	0.833		0.5 ± 0.3	0.5 ± 0.2	0.841
300		$4.7 \pm 0.3^*$	$4.0 \pm 0.6^*$	0.000*		4.2 ± 4.0	3.7 ± 3.0	0.682		0.4 ± 0.2	0.4 ± 0.2	0.904

Means \pm standard deviations are presented. Statistically significant values are presented in bold with an asterisk.



Supplementary Figure S1. Comparison of insulin concentration in subjects with RPH at baseline and follow-up vs. the healthy control group, showing no difference in any time point during 5-h OGTT.

Legend: RPH: reactive postprandial hypoglycemia, OGTT: oral glucose tolerance test.